MCM
AARD

MAI Capital Management’s Aardvark Therapeutics AARD Stock Holding History

MAI Capital Management’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.04K Buy
+276
New +$2.86K ﹤0.01% 4167

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

MAI Capital Management's AARD Position: Q1 2026 in Review

MAI Capital Management opened a new position in Aardvark Therapeutics (AARD) in Q1 2026: 276 shares worth $1.04K. The stake represents ﹤0.01% of the portfolio and ranks #4167 among its holdings.

79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • MAI Capital Management held 276 shares of Aardvark Therapeutics worth $1.04K as of Q1 2026.
  • Aardvark Therapeutics was a new MAI Capital Management position in Q1 2026.
  • Aardvark Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4167 holding.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.